Methylene Blue: The Definitive Guide

What is methylene blue?

Methylene blue, or methylthioninium chloride, is a synthetic phenothiazinium dye and pharmacologically active oxidation-reduction medicine. It has no dietary requirement, food source, deficiency state or recommended intake. The current U.S. injection label covers acquired methemoglobinemia, a condition in which hemoglobin iron cannot carry oxygen normally. [1], [7]

Its medical mechanism is useful but narrow. The body reduces methylene blue to leucomethylene blue, which helps convert ferric iron in methemoglobin back toward functional ferrous hemoglobin. That does not make every oral “mitochondrial” or “nootropic” product equivalent to the prescription injection. [7]

Human oral evidence exists. It includes pharmacokinetic experiments, one 26-person acute brain-imaging and memory study, and a 37-person bipolar adjunctive crossover trial. Each used a defined formulation and context. Together they show real absorption and biological activity, while leaving long-term healthy use, consumer product quality and a general wellness dose unresolved. [2], [3], [4], [5]

Typical Methylene Blue Clinical and Research Protocols

The prescription label also limits moderate or severe renal impairment to a single 1 mg/kg dose and directs alternative treatment if criteria remain after one hour. That exception belongs to monitored methemoglobinemia care, not oral consumer decision-making. [7]

Product and route

Record prescription injection, compounded capsule, aqueous formulation or retail liquid; they are not interchangeable.

Amount

Record concentration, measured volume, amount per administration and total separately; never infer drops from an unknown dropper.

Interaction context

Keep serotonergic medicines, opioids, dextromethorphan, G6PD status, pregnancy and kidney or liver impairment visible.

What is methylene blue commonly used for?

Acquired methemoglobinemia

This is the approved use that anchors the evidence. Methylene blue injection is an oxidation-reduction agent for pediatric and adult acquired methemoglobinemia. The label requires IV access, clinical criteria, methemoglobin monitoring and alternative treatment when response is inadequate. [7]

Acute cognition in healthy adults

Rodriguez and colleagues randomized 26 adults aged 22–62, with 13 receiving one 280 mg immediate-release oral USP capsule and 13 receiving food-colorant placebo. Functional MRI and tasks were repeated 60 minutes later. Task-related imaging showed significant drug-by-time interactions. Correct retrieval responses increased about 7% from baseline within the methylene-blue group (paired-test P < .01), while placebo did not change; the direct drug-by-time interaction for retrieval accuracy only trended and was not significant (P = .09). [4]

The boundaries are substantial: 13 active participants, one exposure, an acute laboratory task, multiple imaging outcomes and no repeated-use or daily-function assessment. Calling this “low dose” repeats the paper’s terminology; it does not create a safe starting dose for retail products.

Residual bipolar symptoms

Alda and colleagues enrolled 37 people with bipolar disorder who were treated with lamotrigine. Their double-blind crossover compared a 15 mg low-dose methylene-blue condition with 195 mg across six months. Depression and anxiety measures improved in the active condition; mania remained low and stable, while cognitive symptoms did not significantly improve. [5]

This is adjunctive psychiatric treatment, not evidence that a healthy person’s mood or cognition improves. The 15 mg condition is also not an inert placebo; it is a low-dose active comparator.

Mitochondrial and redox claims

Mechanistic reviews describe electron cycling, cytochrome oxidase and hormetic effects. These hypotheses help explain interest in brain and mitochondrial research. They do not establish prevention of cognitive decline or longevity benefit in healthy users. [6]

How do forms and labels differ?

Prescription injection, pharmacy-compounded oral preparations, immediate-release USP research capsules, aqueous PK formulations and retail drops differ in route and controls. Aquarium or laboratory dye is not a human product. “Pharmaceutical grade” on a sales page does not substitute for an approved label, licensed dispensing or batch-specific verification.

Methylthioninium chloride is also distinct from reduced methylthioninium or hydromethylthionine formulations and LMTM/HMTM Alzheimer drug-development programs. A trial of one formulation cannot be cited as proof for an arbitrary retail liquid.

How should methylene blue be stored?

The current injection label requires controlled room temperature, no refrigeration or freezing, and protection from light in the original package. Oral or compounded products need their own pharmacy or manufacturer directions. Do not borrow injectable storage rules as proof of a retail product’s shelf life, and never store an unlabeled blue liquid near food or household chemicals. [7]

What does the human evidence show?

Peter and colleagues gave seven volunteers 100 mg orally and intravenously and found much lower whole-blood exposure after oral administration in that protocol. Rat distribution work within the same report also differed by route. Walter-Sack’s later aqueous-formulation study found substantial absolute bioavailability. Both can be true: oral absorption is meaningful, while formulation and route change exposure and distribution. [2], [3]

What are the risks and interactions?

The May 2026 injection label carries a boxed warning that methylene blue may cause serious or fatal serotonin syndrome when combined with serotonergic drugs and opioids. It directs avoidance with SSRIs, SNRIs, MAOIs and opioids; the full interaction section also names bupropion, buspirone, clomipramine, mirtazapine, linezolid and dextromethorphan. Symptoms can include agitation, hallucinations, delirium, autonomic instability, hyperthermia, tremor, rigidity, myoclonus, hyperreflexia, incoordination, seizure, nausea, vomiting or diarrhea. [7], [8]

G6PD deficiency is a contraindication because treatment can cause severe hemolysis and severe anemia. Hemolytic anemia may be delayed by one or more days even outside known deficiency, and the label also covers hypersensitivity, visual or neurologic symptoms, inaccurate pulse-oximeter readings and laboratory-test interference. Blue or green urine can occur, but urine color cannot verify dose, purity or response. [7]

Pregnancy carries potential fetal harm. The label directs stopping breastfeeding during treatment and for up to eight days afterward. Moderate or severe kidney impairment changes repeat-dose decisions, and hepatic impairment may delay clearance and require longer monitoring. These are clinician-level decisions. [7]

What is the legal and regulatory status?

In the United States, an approved prescription injection exists for acquired methemoglobinemia. That approval does not authorize every oral drop, nootropic claim or compounded product. Check the exact finished product and route; a chemical identity record is not a marketing authorization. [1], [7]

In Canada, verify a claimed drug in the Drug Product Database and a claimed natural health product in the Licensed Natural Health Products Database. An online listing or NPN-like number should be checked directly. [9], [10]

Methylene blue is not named individually in the 2026 WADA list. Athletes still need route-specific review because IV infusions may engage the prohibited-method rule depending on volume, setting and medical context, and a finished product can contain undeclared prohibited ingredients. Absence from the name index is not product clearance. [11]

When should use stop?

Seek urgent care for symptoms compatible with serotonin syndrome, severe allergy, seizure, fainting, breathing difficulty, chest pain, severe confusion, new visual or neurologic symptoms, or suspected hemolysis. Do not stop an antidepressant or other prescription medicine to make room for methylene blue without the prescriber. Suspected poisoning or an uncertain retail concentration warrants poison-centre advice.

What should be monitored?

For medical treatment, follow the label and clinical team: methemoglobin response, symptoms, alternative oxygen-saturation assessment when needed, blood counts and hemolysis markers, neurologic or visual effects, kidney and liver context, and interaction observation. [7]

For a clinician reviewing oral exposure, record exact formulation, concentration, amount, route, time, serotonergic medicines, opioids, cough/cold products, symptoms and product evidence. There is no evidence-based home monitoring plan that makes an unverified retail liquid safe.

What does community experience add?

Public reports can surface questions about product concentration, staining, urine color, nausea, headache, sleep or interactions. They cannot identify a bottle, distinguish dose from impurity, estimate serotonin-syndrome incidence or create a safe drop count. No systematic current community sample was assembled, so this guide reports no consensus dose, cycle, stack, onset or longevity protocol.

How does methylene blue compare with related options?

Common questions

Is methylene blue a supplement?

No. It is a pharmacologically active dye-drug with an approved prescription injection. A retail bottle placed in a supplement catalog does not change that identity.

Does it improve memory in healthy adults?

One small acute trial found imaging changes and about 7% higher memory-retrieval accuracy versus baseline within the 13-person methylene-blue group after one 280 mg capsule. The corresponding drug-by-time comparison with placebo was not significant, and the trial did not test long-term function or repeated use. [4]

Is 280 mg a recommended nootropic dose?

No. It is the exact single exposure used in one 26-person experiment, not a consumer recommendation or safe starting point.

Can methylene blue be combined with antidepressants?

The current label has a boxed serotonin-syndrome warning and directs avoidance with serotonergic drugs and opioids. Medication changes require the prescriber. [7]

Why does G6PD status matter?

The injection label contraindicates use in G6PD deficiency because severe hemolysis and severe anemia can occur. [7]

Is oral methylene blue absorbed?

Yes for studied formulations. One 16-person aqueous-formulation study estimated 72.3% absolute bioavailability, with wide variability. Absorption does not prove benefit or product equivalence. [3]

Are blue urine and staining proof that the product works?

No. Discoloration reflects dye exposure, not verified identity, dose, therapeutic response or safety.

Is aquarium methylene blue suitable for people?

No. A laboratory or aquarium product lacks the human-use formulation and controls of a licensed medicine.

Glossary

Plain explanations of methylene-blue evidence and safety terms.

Methemoglobinemia

A condition in which hemoglobin iron is oxidized and cannot carry oxygen normally.

Redox agent

A compound that accepts and donates electrons in oxidation–reduction reactions.

G6PD deficiency

An inherited enzyme deficiency that can make red blood cells vulnerable to oxidative hemolysis.

Serotonin syndrome

A potentially fatal toxicity with mental-status, autonomic, neuromuscular and gastrointestinal features.

Active comparator

A comparison condition containing a pharmacologically active amount rather than an inert placebo.

Absolute bioavailability

The fraction of an administered non-IV dose reaching systemic circulation compared with IV exposure.

Hemolysis

Breakdown of red blood cells, which can lead to anemia and other complications.

Functional MRI

Imaging of task-related blood-oxygen signals; a change does not automatically mean better daily function.

How this guide was researched

Five PubMed/PMC records were checked directly in NCBI for title, authors, journal, volume, pages, DOI and descendant notices. The healthy imaging report was read in full for the exact 280 mg capsule, 13-per-group allocation and 60-minute schedule. The May 2026 DailyMed label supplied the approved IV protocol, boxed warning, contraindications, pregnancy and monitoring boundaries. Official Canadian and WADA resources supplied jurisdiction and sport context.

Explore the sources

Related guides

• Modafinil and Adrafinil
• CoQ10
• PQQ
• Alpha-Lipoic Acid
• Nootropic compounds

Editorial note

This guide keeps the approved IV indication, oral pharmacokinetics, acute healthy cognition, bipolar treatment and retail-product questions separate. It gives the boxed interaction warning and G6PD contraindication the same prominence as possible benefits.